When all Else Fails, Try This: The HeartMate III Left Ventricle Assist Device

Abbas Bitar; Keith Aaronson

doi:10.1016/j.ccl.2023.06.009

When all Else Fails, Try This: The HeartMate III Left Ventricle Assist Device

Cardiol Clin. 2023 Nov;41(4):593-602. doi: 10.1016/j.ccl.2023.06.009. Epub 2023 Jul 27.

Authors

Abbas Bitar¹, Keith Aaronson²

Affiliations

¹ Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Cardiovascular Center, 1500 East Medical Center Drive SPC 5853, Ann Arbor, MI 48109, USA. Electronic address: [email protected].
² Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Cardiovascular Center, 1500 East Medical Center Drive SPC 5853, Ann Arbor, MI 48109, USA.

PMID: 37743081
DOI: 10.1016/j.ccl.2023.06.009

Abstract

Heart failure (HF) is a progressive disease. It is estimated that more than 250,000 patients suffer from advanced HF with reduced ejection fraction refractory to medical therapy. With limited donor pool for heart transplant, continue flow left ventricle assist device (LVAD) is a lifesaving treatment option for patients with advanced HF. This review will provide an update on indications, contraindications, and associated adverse events for LVAD support with a summary of the current outcomes data.

Keywords: Heart failure; HeartMate III; Hemocompatibility-related adverse events; Left ventricle assist device.

Publication types

Review

MeSH terms

Heart Failure* / surgery
Heart Transplantation*
Heart Ventricles / diagnostic imaging
Heart-Assist Devices*
Humans